$8 Billion And Counting: Pharma Paying Its ACA Taxes
This article was originally published in RPM Report
HHS OIG report shows pharma industry fee is being paid, albeit with a few bumps along the way.
You may also be interested in...
Strategies To Ease Short-Term Earnings Pain From Health Reform Include Cost-Cutting, Diversification
With market-based fees and increased Medicaid rebates set to start several years before drug manufacturers will see any benefit of an expanded market from health care reform, consultants are suggesting several ways to counter the short-term negative effect on earnings, including continued cost-cutting and diversification
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.
Eric Bastings will lead Division of Neurology I, which is expected to handle Biogen’s Alzheimer’s drug aducanumab and Sarepta’s refiling of golodirsen for DMD next year.